Document is current
Any future updates will be listed below
-
Authors
Zhang, Ying https://orcid.org/0009-0002-3837-6436
Diez Garcia, Marc
Shah, Sukrut
Joo, Seongjung
Valderrama, Adriana
Zhang, Shujing
Enzinger, Peter C.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03189719 at ClinicalTrials.govDocuments that mention this clinical trial
Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
https://doi.org/10.1136/jitc-2019-000404
First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study
https://doi.org/10.1007/s10388-024-01053-z
Analysis of quality-adjusted survival time without symptoms or toxicity for pembrolizumab plus chemotherapy as treatment for previously untreated participants with advanced or metastatic esophageal cancer
https://doi.org/10.1007/s11136-025-04109-4
First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
https://doi.org/10.1007/s10388-022-00920-x
First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced esophageal cancer: 5-year outcomes from the phase 3 KEYNOTE-590 study.
https://doi.org/10.1200/jco.2024.42.3_suppl.250
First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): Analysis of KEYNOTE-590 and KEYNOTE-859 by tumor type.
https://doi.org/10.1200/jco.2024.42.3_suppl.345
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
https://doi.org/10.1136/jitc-2022-006658
-
Funding
Funding for this research was provided by:
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA)
- License Information
-
More Information
Article History
Received: 16 August 2024
Accepted: 10 November 2025
First Online: 1 February 2026
Declarations
:
: Ying Zhang is an employee of MSD Europe Inc., Brussels, Belgium, and holds stock in Merck & Co., Inc., Rahway, NJ, USA. Marc Diez Garcia has no conflicts of interest to disclose. Sukrut Shah, Seongjung Joo, Adriana Valderrama, and Shujing Zhang are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and hold stock in Merck & Co., Inc., Rahway, NJ, USA. Peter C. Enzinger reports consulting fees from ALX Oncology, Arcus Bioscience, Astellas, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Chimeric Therapeutics, Celgene, Coherus, Daiichi Sankyo, Five Prime, Ideaya, Istari, Legend, Lilly, Loxo, Merck, Novartis, Ono Pharmaceuticals, Servier, Taiho, Takeda, Turning Point Therapeutics, Xencor, and Zymeworks, outside the current work.
